伊布替尼治疗B细胞恶性肿瘤中国专家共识(2019年版)

Chinese expert consensus on the ibrutinib treatment in B-cell malignancies (2019 version)

布鲁顿酪氨酸激酶(BTK)是治疗B细胞恶性肿瘤(BCM)的一个有效靶点,伊布替尼作为首个口服的新型高效BTK抑制剂,已被美国食品药品监督管理局(FDA)批准用于多种BCM的治疗.然而伊布替尼在我国获批上市时间较短,临床使用经验尚少.为了进一步规范伊布替尼在BCM治疗中的临床应用,共识专家组成员根据目前国内伊布替尼应用现状,并结合国内外最新的权威指南及循证医学证据,制定了伊布替尼治疗BCM中国专家共识.

Bruton's tyrosine kinase (BTK) is an effective target for the treatment of B-cell malignancies (BCM), and ibrutinib is the first orally available, novel and high potent inhibitor of BTK approved by the US Food and Drug Administration (FDA) for the treatment of patients with BCM. However, due to ibrutinib launched in China for a short time and many physicians have little clinical experience with it. Therefore, in order to optimization and standardization of clinical applications of ibrutinib in BCM, the Chinese hematology and oncology experts basing on the current status of clinical application of ibrutinib in China and combined with the latest domestic and foreign authoritative guidelines and literature developed the Chinese expert consensus on the ibrutinib treatment in BCM.